| Clinical data | |
|---|---|
| Other names | PiPT; N-Propyl-N-isopropyltryptamine |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H24N2 |
| Molar mass | 244.382 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Propylisopropyltryptamine (PiPT), also known as N-propyl-N-isopropyltryptamine, is a psychedelic drug of the tryptamine family. It reportedly produces hallucinogenic effects that resemble those of other related dialkyl tryptamine derivatives, although PiPT is reportedly relatively weak and short-lasting. It has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada.
According to Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved), PiPT had not yet been evaluated.
PiPT is short for N-propyl-N-isopropyltryptamine. PiPT is a tryptamine, which all belong to a larger family of compounds known as indolethylamines
Analogues of PiPT include methylisopropyltryptamine (MiPT), ethylisopropyltryptamine (EiPT), diisopropyltryptamine (DiPT), and dipropyltryptamine (DPT), among others.
PiPT is not a controlled substance in Canada as of 2025.
PiPT is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
| Tryptamines |
|
|---|---|
| 4-Hydroxytryptamines and esters/ethers |
|
| 5-Hydroxy- and 5-methoxytryptamines |
|
| N-Acetyltryptamines |
|
| α-Alkyltryptamines |
|
| α-Ketotryptamines | |
| Cyclized tryptamines |
|
| Isotryptamines | |
| Related compounds |
|